Company news
CytomX Therapeutics, Inc. news in 2022
CytomX Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023
December 21, 2022
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 19, 2022
CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium
December 6, 2022
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
November 16, 2022
CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
November 16, 2022
CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 7, 2022
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting
November 6, 2022
CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022
October 31, 2022
CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249
September 11, 2022
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051
September 6, 2022
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 3, 2022
CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences
August 2, 2022
CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
July 27, 2022
CytomX Therapeutics Provides Strategic Update
July 12, 2022
CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer
July 5, 2022
CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference
May 31, 2022
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors
May 25, 2022
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 4, 2022
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
April 27, 2022
CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors
April 13, 2022
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
March 22, 2022
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022
March 16, 2022
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update
February 28, 2022
CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference
February 27, 2022
CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
February 21, 2022
CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer
February 6, 2022
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
January 18, 2022
CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
Calls in 2022
- CytomX Therapeutics (NASDAQ:CTMX) Q3 2022 Earnings Call
Nov 8, 2022
Transcript - CytomX Therapeutics (NASDAQ:CTMX) Q2 2022 Earnings Call
Aug 4, 2022
Transcript - CytomX Therapeutics (NASDAQ:CTMX) Q1 2022 Earnings Call
May 5, 2022
Transcript - CytomX Therapeutics (NASDAQ:CTMX) Q4 2021 Earnings Call
Mar 1, 2022
Transcript
Decks in 2022
- 40th Annual J.P. Morgan Healthcare Conference (January 2022)
Conference · 30 slides · Jan 10, 2022